Marco Ruella

The paper identifies a multi-kingdom microbial consortium that normalizes immune responses in laboratory mice, altering cancer outcomes and CAR T cell therapy responses.

This study identifies SPTBN2 as a regulator of immunosuppressive tumor microenvironment and cross-resistance to therapies, showing its role in suppressing CAR T-cell efficacy.

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.

This paper develops anti-CD2 CAR T-cells that overcome fratricide and improve efficacy by incorporating a PD-1:CD2 switch receptor to restore CD2 signaling.

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.